# Apollo Hospitals share price today (Apollo Hospitals Enterprise Ltd, NSE: APOLLOHOSP)

> Apollo Hospitals share price today: ₹8,440.00 at the NSE close on 3 November 2026, up 9.9% in a year. Apollo Hospitals Enterprise (NSE: APOLLOHOSP) is worth ₹1,21,354 crore, trades at a P/E of 57.6 and has closed between ₹6,803.00 and ₹8,957.00 over the past 52 weeks. > Apollo Hospitals Enterprise Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 3% of past readings. APOLLOHOSP · Hospitals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from fewer quarters than usual
- Price: ₹8,440.00 (+9.9% in a year)
- P/E: 57.6× (lower than 97% of the last 11 years)
- Revenue (Jun 2026): ₹7,044 Cr (+20.6% on a year ago)
- Profit (Jun 2026): ₹610 Cr (+38.3% on a year ago)
- Operating margin: 16.0% (+1.0 points on a year ago)
- ROCE: 17%, FY26
- Profit that came in as cash: 156%, last 3 years

The main question: foreign institutions moved −2.2 percentage points over 8 quarters while the business went the other way. ## What is the Apollo Hospitals share price today? Apollo Hospitals Enterprise Ltd's share price was ₹8,440.00 at the close on 3 November 2026. It has been rising for 34 weeks. That is 3.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹6,803 and ₹8,957, and at that close it sat 76% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +489% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Apollo Hospitals this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and best operating margin in 15 quarters. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹7,044 crore, +20.6% on a year earlier. Why: Revenue rose because more patients came to its hospitals and each patient spent more on care. Next results: check whether hospital revenue growth stays on track for 20 percent. From the earnings call on 13 Aug 2026. 2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter profit was ₹610 crore, +38.3% on a year earlier. Why: Profit rose because established hospitals made a higher margin on their revenue. Next results: check whether the digital and insurance businesses stop losing money. From the earnings call on 13 Aug 2026. 3. Best operating margin in 15 quarters Operating margin was 16% in the June 2026 quarter, against 15% a year earlier. Why: Margin rose because more patients came in and each patient spent more, which helped cover fixed costs. From the earnings call on 13 Aug 2026. ## What are Apollo Hospitals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Apollo Hospitals reported revenue of ₹7,044 crore, up 20.6% from ₹5,842 crore a year earlier, and a profit of ₹610 crore, up 38.3% from ₹441 crore. ### Apollo Hospitals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹7,044 crore | ₹5,842 crore | +20.6% |
| Profit | ₹610 crore | ₹441 crore | +38.3% |
| Earnings per share | ₹40.39 | ₹30.10 | +34.2% |
| Operating margin | 16.0% | 15.0% | +1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Apollo Hospitals' management discussed these results on a call held on 13 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Apollo Hospitals share price history? Apollo Hospitals closed at ₹8,440.00 on 3 November 2026, up 9.9% from ₹7,681.00 a year earlier (31 October 2025) and up 90.2% over five years. Its highest weekly close since February 2016 was ₹8,957.00 on 31 July 2026. ### Apollo Hospitals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹7,730.00 | +9.2% |
| 1 month ago · 1 Oct 2026 | ₹8,133.50 | +3.8% |
| 6 months ago · 30 Apr 2026 | ₹7,636.50 | +10.5% |
| 1 year ago · 31 Oct 2025 | ₹7,681.00 | +9.9% |
| 3 years ago · 3 Nov 2023 | ₹5,153.20 | +63.8% |
| 5 years ago · 4 Nov 2021 | ₹4,438.55 | +90.2% |
| 10 years ago · 4 Nov 2016 | ₹1,285.60 | +556.5% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹1,433.60 | +488.7% |
| Highest weekly close since February 2016, also the 52-week high · 31 Jul 2026 | ₹8,957.00 | −5.8% |
| Lowest weekly close since February 2016 · 1 Jun 2018 | ₹927.10 | +810.4% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹6,803.00 | +24.1% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (566 weekly closes from 26 February 2016 to 3 November 2026.)

## What is the latest news on Apollo Hospitals? 3 Nov 2026: Apollo Hospitals closed at ₹8,440.00, up 9.2% on the week and up 3.8% on the month. 14 Aug 2026: ex-date for a dividend of ₹10 a share. ### Earlier

- 13 Aug 2026: Apollo Hospitals held its results call for April to June 2026. Management guided: FY27 hospital revenue growth 18-20%, with management saying it is on track for 20%. - Results for April to June 2026: Revenue up 20.6% and profit up 38.3% on a year earlier. - 16 Feb 2026: ex-date for an interim dividend of ₹10 a share. ## What dividend does Apollo Hospitals pay? Apollo Hospitals paid ₹20 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 0.24% at the ₹8,440.00 close on 3 November 2026. The last was a dividend of ₹10 a share, ex-date 14 August 2026. ### Apollo Hospitals dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 14 Aug 2026 | ₹10 | Dividend | same day |
| 16 Feb 2026 | ₹10 | Interim | same day |
| 19 Aug 2025 | ₹10 | Dividend | same day |
| 14 Feb 2025 | ₹9 | Interim | 15 Feb 2025 |
| 16 Aug 2024 | ₹10 | Dividend | 17 Aug 2024 |
| 20 Feb 2024 | ₹6 | Interim | same day |
| 18 Aug 2023 | ₹9 | Dividend | 19 Aug 2023 |
| 24 Feb 2023 | ₹6 | Interim | same day |
| 18 Aug 2022 | ₹11.75 | Dividend | n/a |
| 18 Aug 2021 | ₹3 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Apollo Hospitals Enterprise Ltd paid out 15% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Apollo Hospitals management say on the latest results call? On the call for April to June 2026, held on 13 August 2026, Apollo Hospitals' management guided: FY27 hospital revenue growth 18-20%, with management saying it is on track for 20%. > “Yes, for this, yes, I believe we're on track to deliver 20%.”
> Suneeta Reddy, Managing Director, on the call for April to June 2026

### What management guided

- FY27 new-hospital operating profit loss maintained at ₹150 crore; quarterly run-rate expected to rise by at least ₹20 crore before easing. - Gurgaon soft launch September, opening October, meaningful inpatient contribution from Q4; total capacity reaches 14,100 beds by FY31, with current overhead supporting 750 beds. - Digital vertical poised for breakeven next quarter; sustainable expenses around ₹80 crore per quarter; insurance planned to break even by end-Q3. - Established hospitals guided to 13-14% revenue growth, new units adding 7% over the next two years; margins to sustain current levels and improve somewhat. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/1052/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 13 August 2026.)

## What is the future of Apollo Hospitals? What is changing in the business? What is changing at Apollo Hospitals, from the latest results and calls: established-hospital growth and operating leverage, complex-care mix and pricing and healthco and digital cost inflection. - Established-hospital growth and operating leverage. Hospital services grew through volume, acuity, pricing, and productivity, with management aiming for continued established-hospital growth. ⚠ estimate
- Complex-care mix and pricing. Healthcare services reported higher acuity volumes, an increase in revenue per patient, and annual pricing provisions. ⚠ estimate
- HealthCo and digital cost inflection. HealthCo expanded profit while digital remains planned for cash breakeven in the next reported quarter. ⚠ estimate
- Diagnostics-led AHLL improvement. Diagnostics growth and margin progression are the stated route to AHLL improvement. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 22 August 2026.)

## What could change the Apollo Hospitals story? What are the risks? The thesis breaks if hospital revenue misses the guided range while operating margin falls below the prior-year level and the delayed Gurgaon opening slips again. ### Each change stops working if

- Established-hospital growth and operating leverage: Established-hospital growth slows while new-hospital losses rise before utilization improves. - Complex-care mix and pricing: Complex-care volumes or pricing resets slow before replacement capacity contributes. - HealthCo and digital cost inflection: Digital cash breakeven does not occur in the next quarter or insurance costs increase again. - Diagnostics-led AHLL improvement: Diagnostics growth falls below management’s stated goal or AHLL margin does not progress. ### The main risks

- Gurgaon commissioning delay: Gurgaon has moved from an earlier operationalization date to the fourth quarter of the fiscal year. ⚠ estimate
- Digital breakeven slips again: Digital breakeven is now expected in the upcoming quarter after prior timing changes. ⚠ estimate
- Working-capital cycle lengthens during capital spending: Cash conversion remains above reported profit, but the cash conversion cycle moved from negative to positive days. ✓ fact

(Our read after the latest results, written 22 August 2026.)

## What to watch in Apollo Hospitals' next results? When Apollo Hospitals reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Digital vertical cash breakeven in the upcoming quarter - test whether insurance build-out and one-time costs stop delaying standalone economics. - What to check (from the call)
- Digital vertical cash breakeven in the upcoming quarter - test whether insurance build-out and one-time costs stop delaying standalone economics. - New-hospital loss trajectory before easing - check whether the pre-Gurgaon rise stays within the full-year framework and Financial District reaches breakeven. - Gurgaon commissioning and first inpatient ramp - verify opening execution and meaningful revenue contribution after launch. - AHLL diagnostics growth and margin progression - check continued improvement as focus concentrates on diagnostics and primary care. ## Which stock lists is Apollo Hospitals on? Apollo Hospitals is on one of our India lists: Nifty 50 companies. [Nifty 50 companies](https://www.sectoralpha.in/nifty-50-stocks-list)

## Is Apollo Hospitals profitable? Apollo Hospitals Enterprise Ltd earned ₹610 Cr of net profit in the Jun 2026 quarter, +38.3% on the same quarter a year earlier. That is the 11th quarter in a row of profit growth. Full-year FY26 profit was ₹2,003 Cr. Over 10 years profit has grown 23.9% a year on average. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned ₹441 Cr. For the full year, FY26 profit was ₹2,003 Cr (+33.1% on the year before). Why profit moved: revenue changed +20.6% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +33.0% and revenue +17.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Apollo Hospitals make, and is it growing? Apollo Hospitals Enterprise Ltd reported ₹7,044 Cr of revenue in the Jun 2026 quarter, +20.6% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 15.2% a year on average. The last full year, FY26, came in at ₹25,228 Cr. Why this happened. AHLL reported revenue growth, higher EBITDA, and a narrower profit loss. Management identifies diagnostics as the principal source of margin expansion and has narrowed focus toward diagnostics and primary care. The last four reported quarters add to ₹26,431 Cr. FY26 revenue was ₹25,228 Cr, +15.8% on the year before. Recent pace: the last four quarters grew +17.2% on average, against 15.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +17.2%, against +15.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +33.2%, against +42.0% a year (rolling over). ## How much of every ₹100 of sales does Apollo Hospitals keep? Apollo Hospitals Enterprise Ltd's operating margin was 16.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 10.0% and 16.0%. The latest quarter is within that range. Why this happened. The operating-leverage catapult applies because management attributes margin improvement to operating leverage, clinical case mix, and productivity optimization. The latest quarter also shows a higher operating margin than the comparable quarter. The off-switch is a failure of established-hospital growth to offset start-up losses from new units. Why the margin moved: operating margin changed +0.9 percentage points on the year while gross margin changed +1.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Apollo Hospitals' profit turning into cash? Over the last 3 years, 156% of Apollo Hospitals Enterprise Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹2,856 Cr of operating cash against ₹2,003 Cr of profit. After ₹2,271 Cr of spending on assets, ₹585 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 156% of profit came in as cash: the cash cycle got 15 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.8× depreciation over three years. The next section checks what that spending is building. ## Where does Apollo Hospitals' cash go? Apollo Hospitals Enterprise Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 3 days in FY26, up from −12 days in FY21. It spent ₹6,495 Cr on assets over the last 3 years. Customers take 50 days to pay, and stock sits for 15 days on average. At FY26 sales of ₹25,228 Cr, each day of that cycle ties up about ₹69.1 Cr, so roughly ₹207 Cr is tied up in the business at any time. FY26: customers took 50 days to pay and stock sat for 15 days, about 0.5 months of sales sitting as stock, for a full cycle of 3 days, longer than FY21's −12. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 15 days. Customers pay about 50 days after that. Suppliers are paid at 63 days. Together that makes the 3-day cycle. Spending on assets: ₹6,495 Cr over the last 3 years, against ₹2,321 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1,032 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Apollo Hospitals' P/E ratio, and how does it compare with its own history? Apollo Hospitals Enterprise Ltd's P/E is 57.6×, near the low end of its own history: it has been lower only 3% of the time. Its usual P/E (the middle reading) is 75.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +34.3% while the price moved +9.9%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +13.7% a year; about +29.9% a year came from earnings growth and about −16.2 percentage points from the multiple (the market paying less); over 10 years the price moved +20.7% a year; about +24.5% a year came from earnings growth and about −3.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 6.3% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What growth does the Apollo Hospitals share price assume? Worked out from its price on 25 August 2026, Apollo Hospitals Enterprise Ltd's share price assumed profit growth of about 29.4% a year. Over the past 10 years its profit actually grew 23.9% a year. Today its P/E is 57.6×, lower than 97% of its own last 11 years. This is a one-day reading, taken on 25 August 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Apollo Hospitals business getting better or worse? Apollo Hospitals Enterprise Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 17.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: steady growth with healthy returns is how a business compounds over time. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is the Apollo Hospitals story, and has it been checked? Apollo Hospitals Enterprise Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: MID EXPANSION. Still open: The thesis breaks if hospital revenue misses the guided range while operating margin falls below the prior-year level and the delayed Gurgaon opening slips again. Our read, 22 August 2026. From the numbers. From the price. Price stage 2, week 34, above its 200-day line, relative strength rising. From the research. Where they disagree. What is proven. What is not proven yet. The thesis breaks if hospital revenue misses the guided range while operating margin falls below the prior-year level and the delayed Gurgaon opening slips again. What would change our mind. The thesis breaks if hospital revenue misses the guided range while operating margin falls below the prior-year level and the delayed Gurgaon opening slips again. The test written in advance. The thesis breaks if hospital revenue misses the guided range while operating margin falls below the prior-year level and the delayed Gurgaon opening slips again. Measured by: the thesis as written as stated by the next result. The test written in advance. The test written in advance. Gurgaon commissioning delay. Measured by: Gurgaon commissioning delay Gurgaon operational before Q4 FY27 by the next result. What the company does. Revenue and reported profit rose in the latest quarter, with operating margin above the prior-year level. The key swing factors are delivery of hospital-growth guidance, digital breakeven, the Gurgaon opening, and conversion of new capacity into utilization. What the surface reading misses. What the surface reading misses. The surface reading is: A higher operating margin reads as proof of improved profitability. The research reads it further: The level is near the top of the historical margin band, so part of trailing earnings may be cyclical or execution-sensitive rather than a permanent base. Lever 1 · Operating leverage: building. Hospital services grew through volume, acuity, pricing, and productivity, with management aiming for continued established-hospital growth. What proves it keeps working: Established-hospital growth and operating leverage. It stops working if Established-hospital growth slows while new-hospital losses rise before utilization improves. Lever 2 · Value-added mix: building. Healthcare services reported higher acuity volumes, an increase in revenue per patient, and annual pricing provisions. What proves it keeps working: Complex-care mix and pricing. It stops working if Complex-care volumes or pricing resets slow before replacement capacity contributes. Lever 5 · Regulatory approval: building. HealthCo expanded profit while digital remains planned for cash breakeven in the next reported quarter. What proves it keeps working: HealthCo and digital cost inflection. It stops working if Digital cash breakeven does not occur in the next quarter or insurance costs increase again. Lever 14 · A bigger market to serve: building. Diagnostics growth and margin progression are the stated route to AHLL improvement. What proves it keeps working: Diagnostics-led AHLL improvement. It stops working if Diagnostics growth falls below management’s stated goal or AHLL margin does not progress. Sources: our stock research file (22 August 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Apollo Hospitals management deliver what it promised? What Apollo Hospitals Enterprise Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Hospital Revenue Growth Outlook Raised · 13 August 2026. In the Feb 2026 call, management framed established-hospital growth at 12%-14% and incremental beds at another 3%-4%, implying a mid-teens trajectory. In the Aug 2026 call, management moved to a 20% hospital revenue goal and separately described a 7% contribution from new hospitals, but did not clearly reconcile the higher new-hospital contribution or quantify the assumptions behind the change. Gurgaon Operationalization Delayed Again · 13 August 2026. In Feb 2026, management expected Gurgaon to be operational in Q2 FY27 after an acknowledged 2-3 month environmental delay. In Aug 2026, the timeline moved to Q4 FY27, a further two-quarter delay, without a specific explanation for why the previously expected Q2 date was no longer achievable. Material Delay in New Bed Operationalization Timeline · 21 May 2026. In the Feb 2026 call, management guided that approximately 40% to 50% of their 1,500 new bed pipeline would be operationalized by Q1. However, in the May 2026 call, management significantly lowered this near-term delivery, revealing that only 185 beds had been operationalized and pushed the 500-600 bed benchmark to the middle of the year without a clear operational justification for the delayed ramp-up. Digital Breakeven Goalpost Moved · 11 February 2026. Management explicitly guided for the digital business to achieve breakeven by the end of FY26 in the August 2025 call, reinforcing this goal was 'well on track.' However, in the latest call, they have pushed this goal out to Q1 FY27, citing issues with insurance income recognition logic. Earlier call (Aug 2025): “This is an excellent outcome, and we are well on track to achieve break-even in the digital business by the end of this fiscal.” Later call (Feb 2026): “Consequently, we expect cash EBITDA breakeven to move to Q1 FY27.”

Every quote above is taken word for word from the company’s own earnings calls. ## What is Apollo Hospitals management's track record? No company-specific SEBI, CBI or ED action surfaced; the enforcement result does not identify Apollo as the noticee. 2.49% Promoter shares pledged

Sources:

- [alphaspread.com](https://www.alphaspread.com/security/nse/apollohosp/investor-relations/earnings-call/q1-2026)
- [sebi.gov.in](https://www.sebi.gov.in/sebi_data/attachdocs/may-2026/ORDER_1780029095.pdf)
- [marketsmojo.com](https://www.marketsmojo.com/stocks-analysis/financial-shareholding/apollo-hospitals-423292-1)

(Checked 30 August 2026.)

## How much does Apollo Hospitals earn on its capital? Apollo Hospitals Enterprise Ltd earned a ROCE of 17% in FY26. That is up from a low of 7% in FY18. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 7.9% net margin and 1.14× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.9% net margin × 1.14× asset turnover × 2.34× leverage (assets divided by equity) ≈ 21.1% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 6.3% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Apollo Hospitals have too much debt? Apollo Hospitals Enterprise Ltd had ₹8,493 Cr of borrowings against ₹9,480 Cr of equity in FY26, so its debt is 0.90× its equity. Its operating profit is 8 times its interest bill. Over 5 years borrowings went from ₹4,160 Cr to ₹8,493 Cr. Over the last 3 of those years it spent ₹6,495 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 6.3% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Apollo Hospitals shareholding pattern? Foreign institutions cut their stake in Apollo Hospitals Enterprise Ltd by 2.2 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 43.2% of the company. Domestic institutions moved +2.1 points over the same period, to 22.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −2.2 points over 8 quarters, to 43.2%; Domestic institutions: +2.1 points over 8 quarters, to 22.1%; Promoters: −1.3 points over 8 quarters, to 28.0%. Why the owners changed: foreign institutions moved −2.2 points and domestic institutions +2.1 points over 8 quarters, while promoters moved −1.3 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Apollo Hospitals from balance-sheet trouble? For Apollo Hospitals Enterprise Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. Why this happened. HealthCo revenue and profit rose in the latest call, while management said core pharmacy and diagnostics were expanding and insurance remained in build-out mode. Digital breakeven is a concrete gating event because prior timing moved and the latest call places it in the upcoming quarter. ## How does Apollo Hospitals rank in its industry? 68.5 out of 100, rank 3 of 20 in Hospitals, with 78% of the evidence available. Apollo Hospitals Enterprise Ltd scores 68.5 out of 100 against the 20 companies it is compared with in Hospitals, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 24 + 15.2 + 12.7 + 16.6 = 68.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Apollo Hospitals compared with? Apollo Hospitals ranks 3 of 20 Hospitals companies on the 4-Factor Sector Score, with 68.5 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.1/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23.1 + 14.1 + 12.5 = 80.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.5/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.5 + 11.1 + 13.8 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. Apollo Hospitals Enterprise Ltd this page APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.4/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.4 + 12.5 + 11.6 = 62.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.2 + 18.5 + 9.1 = 61.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.8/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.8 + 8 + 16.7 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 17.3 + 5.5 + 14.2 = 50.5 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.3 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.7 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.8 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.2 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Apollo Hospitals in size? Apollo Hospitals is the largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Manipal Health Enterprises, Max Healthcare Institute, Aster DM Quality Care, Fortis Healthcare, Narayana Hrudayalaya and Global Health. ### Hospitals companies close in size

1. Apollo Hospitals Enterprise Ltd ₹1,21,469 crore
2. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) ₹88,018 crore
3. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) ₹83,705 crore
4. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ₹59,374 crore
5. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) ₹57,992 crore
6. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) ₹35,154 crore
7. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) ₹34,156 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [Cummins India Ltd](https://www.sectoralpha.in/stocks/cummins-india-ltd) ₹1,23,426 crore · Gensets
2. [Bank of Baroda](https://www.sectoralpha.in/stocks/bank-of-baroda) ₹1,23,389 crore · Banks - PSU
3. Apollo Hospitals Enterprise Ltd ₹1,21,469 crore
4. [Hitachi Energy India Ltd](https://www.sectoralpha.in/stocks/hitachi-energy-india-ltd) ₹1,21,348 crore · Electrical Equipments/HVDC
5. [Billionbrains Garage Ventures Ltd](https://www.sectoralpha.in/stocks/billionbrains-garage-ventures-ltd) ₹1,20,152 crore · Finance - Capital Markets - Brokers

## What else do people ask about Apollo Hospitals? ### What is Apollo Hospitals's share price today? Apollo Hospitals Enterprise Ltd's share price is ₹8,440.00, +9.9% over the past year. The whole company is worth ₹1,21,354 Cr on the market. In the last 52 weeks it traded between ₹6,803 to ₹8,957; today it is 76% of the way up from the low, 3.4% above its 200-day average (as of 3 November 2026). ### What were Apollo Hospitals's latest quarterly results? Apollo Hospitals Enterprise Ltd reported revenue of ₹7,044 Cr and net profit of ₹610 Cr for the Jun 2026 quarter. Revenue rose 20.6% and profit rose 38.3% compared with a year earlier. Earnings per share were ₹40.39. The operating margin was 16.0%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Apollo Hospitals's market cap? Apollo Hospitals Enterprise Ltd's market capitalisation is ₹1,21,354 Cr at a share price of ₹8,440.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Apollo Hospitals performing? Apollo Hospitals Enterprise Ltd's share price has been rising for 34 weeks. In its latest quarter, revenue rose 20.6% and profit rose 38.3% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Apollo Hospitals's share price go up? This page does not forecast Apollo Hospitals Enterprise Ltd's share price. What it shows instead: the share price is ₹8,440.00, and it has been rising for 34 weeks. Its P/E of 57.6× is higher than 3% of its own last 11 years (as of 3 November 2026). ### Who owns Apollo Hospitals? Promoters own 28.0% of Apollo Hospitals Enterprise Ltd, foreign institutions 43.2%, domestic institutions 22.1% and the public 6.5% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 2.2 percentage points over 8 quarters (as of 3 November 2026). ### Where is Apollo Hospitals in its business cycle? Apollo Hospitals Enterprise Ltd's FY26 operating margin was 15.0%, against a 13-year range of 10.0% to 16.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 16.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Apollo Hospitals story? The main question: foreign institutions moved −2.2 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Apollo Hospitals a stock worth studying right now? What the numbers show: Apollo Hospitals Enterprise Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 3% of past readings. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Apollo Hospitals share price forecast for 2026? What management itself guided: FY27 hospital revenue growth 18-20%, with management saying it is on track for 20%. What is changing at Apollo Hospitals, from the latest results and calls: established-hospital growth and operating leverage, complex-care mix and pricing and healthco and digital cost inflection. What would change the story: The thesis breaks if hospital revenue misses the guided range while operating margin falls below the prior-year level and the delayed Gurgaon opening slips again. ### Where does this page get Apollo Hospitals' management information? From Apollo Hospitals' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Nifty 50 companies: https://www.sectoralpha.in/nifty-50-stocks-list

This is research, not advice. We’re not SEBI-registered.